Drugs / Meningococcal A Conjugate Vaccine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03299426 Comparator | Feb 2018 → Jan 2025 overdue | typhoid fever | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal A Conjugate Vaccine | “Meningococcal A Conjugate Vaccine (MCV-A)” NCT03299426 ↗ |
| Known as | MCV-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03299426 ↗ |
| Modality | Vaccine | “meningococcal capsular group A conjugate (MenA) vaccine” PMID 38281499 ↗ Jan 2024 |
| Route | Intramuscular | “Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.” NCT03299426 ↗ |